Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia
The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 98-100
DOI: 10.58347/tml.2026.1757b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.
Themen: Demenz
Abstract (Originalsprache)
Auvelity (Axsome), an extended-release fixed-dose combination of dextromethorphan and bupropion that was approved by the FDA for treatment of major depressive disorder in 2022,1 has now been approved for treatment of agitation associated with dementia due to Alzheimer's disease (AD). It is the second product to be approved in the US for this indication; the oral second-generation antipsychotic drug brexpiprazole (Rexulti) was approved in 2023.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia. The Medical Letter on Drugs and Therapeutics, 68(1757), 98-100. https://doi.org/10.58347/tml.2026.1757b
Vancouver
Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):98-100. doi:10.58347/tml.2026.1757b
BibTeX
@article{euvimed2026,
title = {Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1757},
pages = {98--100},
doi = {10.58347/tml.2026.1757b}
}
EUVIMED